reason report
lower estim reflect underli
bottom line share trade today think deservedli
reaction complet intern investig histor
report foreign currenc gain believ fulli remov
overhang stock coupl strong highlight
acceler growth momentum busi mix make
rel one insul large-cap med-tech compani
on-going quickli evolv pandem posit
continu near medium-term out-performance view
surprisingli pull guidanc due uncertainti around
manag provid color impact
see thu far purchas pattern capit equip
expect chang mid long term near term purchas
pattern may delay pd periton dialysi resili
done home acut therapi expect see increas
demand continu renal replac therapi critic icu/
hospit patient suppli chain side
abl mitig suppli constraint disrupt compon
china itali compani expect extra cost
requir ship raw materi certain geographi
believ one compani within coverag
univers rel less exposur elect procedur
exposur hospit essenti especi acut
therapi take opportun lower
estim reflect think worst-cas scenario
impact -- essenti assum elect procedur
exposur anesthesia advanc surgeri
cancel recoveri think
repres draconian scenario reflect real
increment benefit acut therapies/med deliveri
busi would rather posit rais
number within next weeks/month vs lower
beyond continu view growth acceler
stori beyond exit lrp near top-lin
growth organ ahead overal med-tech market mid-single-
digit rang possibl even faster growth overal via acquisit
reiter op pt pt rang
dcf valuat deriv base case upsid scenario
supplement ev/fcf ev/ebitda price-to-earnings analys
estim price-to-earnings perspect pt reflect multipl
ep estim repres stabl multipl
current level pe ep estim
pe multipl large-cap med-tech group
ew averag
pe sale growth acceler strong free cash flow
compani inform svb leerink llc research
revenu mm ep includ stock compens expens
medic suppli devic
deriv dcf valuat rang
supplement ev/fcf ev/ebitda
price-to-earnings lt ep growth
year price history/av daili volume mil
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
think modest premium group averag justifi
sale estim move lower reflect potenti
impact estim basic unchang expect
neg impact across med-tech univers procedur volum
delay magnitud durat impact difficult
quantifi still fluid situat howev rather
conserv point rais estim year
progress posit lower estim later
lower sale estim reflect neg impact primarili
anesthesia advanc surgeri cut estim
given
anesthesia repres ww sale expos
elect procedur
advanc surgeri also exposur elect
procedur busi essenti assum
elect procedur cancel number
procedur done done hospit re-
ramp capac post mid-year return normalci think
potenti upsid conserv estim like driven
potenti benefit acut therapies/med deliveri
procedur rebound procedur volum delay
recoup elimin altogeth
rate share outperform price target believ sale
growth acceler stori remain underappreci street bax lrp sale
compound-annual-growth-rate time-frame oper margin ramp
immedi post-spin us well-posit
exit lrp long-rang plan near top-lin growth organ ahead
overal med-tech market mid-single-digit rang possibl even faster growth overal via
given compani solid execut to-dat steadi stream upcom new product launch
addit clari fill gener inject busi increasingli confid
continu drive upsid current long-term growth margin target
believ margin expans stori alreadi least partli price stock
manag current guid oper margin
see room upsid margin ramp believ major upsid
alreadi price share level
sale perspect also see potenti upsid current top-lin growth target
compound-annual-growth-rate time-frame driven new product launch geograph
expans someth feel underappreci street pipelin biggest
driver sale growth acceler next five year expect launch
new product new product expect make total sale
ramp expect signific growth pd periton dialysi gener
inject biosurgeri core growth contributor drive top line grow
solid mid-singl digit higher
addit strong free cash flow gener capabl free cash flow target
vs potenti upsid free cash flow view
increas financi flexibl invest busi drive even faster sale
growth acceler invest inorgan outsid opportun supplement top-
bottom-lin growth
overal find bax margin expans stori compel believ investor
underappreci bax sale growth reacceler stori also compani cash-
gener capabl believ ebitda repres relev
measur valu compani vs price earn combin
discount cash flow analysi ev/ebitda ev/fcf arriv price
next month believ share trade
rang dcf valuat deriv base case upsid scenario
supplement ev/fcf ev/ebitda analys price-to-earnings perspect pt reflect
multipl ep estim repres stabl multipl current
level pe ep estim pe multipl
large-cap med-tech group ew
averag pe sale growth acceler strong free cash flow
think modest premium group averag justifi
risk includ failur execut margin expans initi new product launch delay
possibl acquisit either dilut perceiv further baxter growth goal
could pressur stock
dollar million except per share data
good sold
research develop expens
pre-tax incom continu
revenu
consensu incom statement item includ contributor factset
consensu detail revenu item visibl alpha
consensu
compani report factset consensu visibl alpha consensu svb leerink estim
dollar million except per share data
good sold
research develop expens
pre-tax incom continu oper
revenu
consensu incom statement item includ contributor factset
consensu detail revenu item visibl alpha
consensu
compani report factset consensu visibl alpha consensu svb leerink estim
dollar million except asp
good sold
research develop expens
pre-tax incom continu oper
net incom compani
non-control interest incom loss discontinu oper net tax
sg sale
 sale
oper expens sale
compani report svb leerink estim
constant currenc
revenu report
constant currenc
revenu report
revenu report
constant currenc
revenu report
constant currenc basi
revenu report
constant currenc basi
revenu report
constant currenc basi
revenu report
constant currenc basi
revenu report
revenu report
constant currenc basi flat
oper
compani report svb leerink estim
type event
event trial detail
date known
up/down
expect
svb leerink llc equiti research compani file
brand
pd solut system improv patient access
launch innov home periton dialysi
hdx enabl theranova new dialysi
therapi patient end-stag renal diseas
